DE69129921D1 - Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten - Google Patents

Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten

Info

Publication number
DE69129921D1
DE69129921D1 DE69129921T DE69129921T DE69129921D1 DE 69129921 D1 DE69129921 D1 DE 69129921D1 DE 69129921 T DE69129921 T DE 69129921T DE 69129921 T DE69129921 T DE 69129921T DE 69129921 D1 DE69129921 D1 DE 69129921D1
Authority
DE
Germany
Prior art keywords
treatment
cataracts
prostaglandin derivatives
keto prostaglandin
keto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69129921T
Other languages
English (en)
Other versions
DE69129921T2 (de
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of DE69129921D1 publication Critical patent/DE69129921D1/de
Publication of DE69129921T2 publication Critical patent/DE69129921T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
DE69129921T 1990-04-04 1991-04-03 Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten Expired - Lifetime DE69129921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9089590 1990-04-04
JP22164690 1990-08-22
JP2931091 1991-01-29

Publications (2)

Publication Number Publication Date
DE69129921D1 true DE69129921D1 (de) 1998-09-10
DE69129921T2 DE69129921T2 (de) 1999-01-14

Family

ID=27286510

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129921T Expired - Lifetime DE69129921T2 (de) 1990-04-04 1991-04-03 Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten

Country Status (11)

Country Link
US (2) US5212324A (de)
EP (1) EP0453127B1 (de)
KR (1) KR970005172B1 (de)
AT (1) ATE169219T1 (de)
AU (1) AU644148B2 (de)
CA (1) CA2039420C (de)
DE (1) DE69129921T2 (de)
DK (1) DK0453127T3 (de)
ES (1) ES2119762T3 (de)
GR (1) GR3027666T3 (de)
TW (2) TW249226B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (de) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
DE69434617D1 (de) * 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
SE9403160D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
CN102126998B (zh) * 1996-06-10 2013-06-12 苏坎波公司 内皮素拮抗剂
US5977173A (en) * 1997-09-09 1999-11-02 Wos; John August Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists
DE69809268T2 (de) * 1997-09-09 2003-08-28 Procter & Gamble Aromatische c16-c20-substituierte tetrahydro-prostaglandine und ihre verwendung als prostaglandin f agonisten
PT978284E (pt) 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
HUP0300391A3 (en) * 2000-03-16 2008-05-28 Sucampo Ag Use of prostaglandin related compounds for preparation of composition for use in treatment of ocular hypertension and glaucoma
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
CN1443070A (zh) 2000-03-24 2003-09-17 苏坎波公司 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
JP2004521960A (ja) * 2001-08-23 2004-07-22 スキャンポ・アーゲー 高眼圧症および緑内障の処置のための方法および組成物
MXPA04002006A (es) 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
DK1562604T3 (da) * 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
CN1753680B (zh) 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
ES2431640T3 (es) 2003-08-21 2013-11-27 Sucampo Ag Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7321057B2 (en) * 2004-08-02 2008-01-22 R-Tech Ueno, Ltd. Method for manufacturing prostaglandin analogue
ES2375082T3 (es) 2005-01-27 2012-02-24 Sucampo Ag Composición para el tratamiento de trastornos del sistema nervioso central.
DK1853271T3 (da) 2005-03-04 2011-01-24 Sucampo Ag Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
PT1871380E (pt) * 2005-04-12 2011-11-21 Sucampo Ag Utilização combinada de composto de prostaglandina e inibidor de bomba de protões para o tratamento de distúrbios gastrointestinais
WO2007086536A2 (en) 2006-01-24 2007-08-02 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
KR101465269B1 (ko) * 2006-01-24 2014-11-26 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
BRPI0708891A2 (pt) * 2006-03-13 2011-06-28 R Tech Ueno Ltd composição aquosa
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CN103561748A (zh) 2011-04-07 2014-02-05 苏坎波公司 治疗眼疲劳的方法
NZ620300A (en) 2011-08-05 2015-09-25 Sucampo Ag Method for treating schizophrenia
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
AR105029A1 (es) 2015-06-19 2017-08-30 Sucampo Ag Composición farmacéutica que comprende derivado de ácido graso

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (de) * 1984-02-29 1985-12-11 The Upjohn Company Therapeutische Anwendung von Protaglandinen
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
DE3876050T2 (de) * 1987-09-18 1993-03-25 R Tech Ueno Ltd Okulare hypotensivagenzien.
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
DE68906193T2 (de) * 1988-05-23 1993-08-05 Ueno Seiyaku Oyo Kenkyujo Kk Hypersphyxia verursachende zusammensetzung.
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0366279B1 (de) * 1988-10-01 1994-09-21 R-Tech Ueno Ltd. Okulare hypotensive Mittel
TW205508B (de) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Also Published As

Publication number Publication date
CA2039420A1 (en) 1991-10-05
DE69129921T2 (de) 1999-01-14
US5686487A (en) 1997-11-11
TW249226B (de) 1995-06-11
ES2119762T3 (es) 1998-10-16
EP0453127A2 (de) 1991-10-23
KR910018027A (ko) 1991-11-30
CA2039420C (en) 1996-12-10
AU644148B2 (en) 1993-12-02
EP0453127A3 (en) 1992-12-09
ATE169219T1 (de) 1998-08-15
KR970005172B1 (ko) 1997-04-14
DK0453127T3 (da) 1998-10-26
GR3027666T3 (en) 1998-11-30
TW224942B (de) 1994-06-11
EP0453127B1 (de) 1998-08-05
US5212324A (en) 1993-05-18
AU7404791A (en) 1991-10-10

Similar Documents

Publication Publication Date Title
DE69129921D1 (de) Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
DE69213057T2 (de) Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
DE69118978D1 (de) Behandlung von entzündlichen Erkrankungen mit 15-Ketoprostaglandinen
ATE132749T1 (de) Behandlung der hepatobilären erkrankung mit 15- ketoprostaglandin-derivaten
DE69032000T2 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
DE69106777D1 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
DE69123892D1 (de) Behandlung von Katarakt mit prostacyclinverbindungen
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
ATE117554T1 (de) Behandlung von männlichen, hormonabhängigen krankheiten mit cyclodextrinen und derivaten davon.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SUCAMPO AG, ZUG, CH